Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 9/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.45 |
| ▸ | MC4R | P32245 | 6/20 | 0.44 |
| ▸ | MC5R | P33032 | 3/20 | 0.43 |
| ▸ | MC3R | P41968 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9876987 | 1.00 | OPRD1 (0.48) | OPRD1OPRK1OPRM1OPRL1MC4R | |
| SCHEMBL9876991 | 1.00 | OPRD1 (0.48) | OPRD1OPRK1OPRM1OPRL1MC4R | |
| SCHEMBL18038731 | 0.85 | OPRL1 (0.59) | OPRD1OPRK1OPRM1OPRL1 | |
| SCHEMBL9312223 | 0.85 | LMNA (0.50) | OPRD1OPRK1OPRM1MC4RMC5R | |
| SCHEMBL9312231 | 0.85 | LMNA (0.50) | OPRD1OPRK1OPRM1MC4RMC5R | |
| SCHEMBL9312229 | 0.85 | LMNA (0.50) | OPRD1OPRK1OPRM1MC4RMC5R | |
| SCHEMBL16423480 | 0.84 | KMT2A (0.51) | OPRD1OPRK1OPRM1OPRL1MC4R | |
| SCHEMBL2579926 | 0.78 | OPRD1 (0.48) | OPRD1OPRK1OPRM1 | |
| SCHEMBL3441859 | 0.77 | OPRM1 (0.60) | OPRD1OPRK1OPRM1OPRL1MC4R | |
| SCHEMBL3024931 | 0.76 | KMT2A (0.51) | OPRD1OPRK1OPRM1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |